Low-intensity pulsed ultrasound does not influence bone healing by distraction osteogenesis: a multicentre double blind randomised control trial by Simpson, Hamish et al.
Abstract
Aim To assess efficacy of low intensity pulsed ultrasound (LIPUS) to accelerate or enhance the rate of bone healing in adult patients.
Patients and Methods Sixty-two skeletally mature adults undergoing limb lengthening or bone transport by distraction osteogenesis were randomised to either an active (n=32) or a placebo (n=30) ultrasound device. A standardised corticotomy was performed in the proximal tibial metaphysis and a circular frame (Ilizarov) was used in all patients. The rate of distraction was also standardised. Primary outcome measure was time ready for removal of frame after adjusting for distraction length (days/cm) for both intension to treat (ITT) and per protocol (PP). The assessor was blind to treatment group. Secondary outcome was to identify covariates affecting time to frame removal.
Results There was no difference in the time to frame removal between the two groups for the ITT (difference 5.0days/cm, 95% CI −8.2 to 18.21; p=0.226) or the PP (difference in favour of the control group was 10.1days/cm, 95% CI −3.2 to 23.4; p=0.054). Current smoking status was the only covariate identified to increase the frame removal time (hazard ratio 0.47, 95% CI 0.22 to 0.97; p=0.042). 
Conclusions LIPUS does not influence the rate of bone healing. 
Take home message: 
	LIPUS does not accelerate bone healing by distraction osteogenesis 
	Smoking status may influence bone healing.
Level of Evidence: Level I Therapeutic study, randomised control trial
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Introduction
Fractures are a great source of morbidity for patients and result in a significant socioeconomic burden upon society.1 The length of time taken for a fracture to unite is an important factor in a patient’s recovery from their injury, with reduced healing time resulting in less patient morbidity and associated financial costs.2 Multiple factors have been demonstrated to influence fracture repair, such as smoking and nonsteroidal anti-inflammatory drugs.3 Interventions to accelerate fracture healing have been described, and more recently a growing body of evidence supporting the use of low-intensity pulsed ultrasound (LIPUS) to accelerate bone healing has been recognised.4 The exact mechanism by which LIPUS induces fracture healing is not known, but it may be attributed to induced low level mechanical stimuli at the fracture site which in turn accelerates healing.5 
	Recent clinical evidence supports the use of LIPUS for patients sustaining long bone fractures with delayed healing, defined as taking longer than 3 months to heal.4 This evidence has resulted in the National Institute of Clinical Excellence supporting the use of LIPUS for patients with delayed fracture healing.6  Clinical evidence to support the LIPUS for use in acute fractures remains unclear.7 Early double blind randomised controlled trials (RCTs) by Heckman et al8 and Kristiansen et al9 demonstrated accelerated fracture healing in patients undergoing LIPUS for acute tibial and distal radial fractures, respectively. However, more recent RCTs have not observed any difference in fracture healing with the use of LIPUS for acute clavicle10 or ankle ADDIN REFMGR.CITE 11 fractures. Due to this conflicting data a recent Cochrane review concluded that there was insufficient evidence to support the routine use of LIPUS for acute fractures.7 The authors of this Cochrane review also demonstrated heterogeneity of the RCTs and a reported high rate of lost to follow up rates for the included trails, which may explain the negative conclusion.
Distraction osteogenesis is a technique that creates new bone. It is used for limb lengthening and to fill bone gaps caused by trauma, infection, tumours and various other conditions.12 The technique was pioneered by Ilizarov and has become a widely accepted orthopaedic procedure and is indicated for a diverse range of patients. The technique entails dividing the bone and after a short latency period gradually pulling apart the bone segments, most commonly with an external frame, at a controlled rate. The period of time the patient requires the frame is variable and dependent upon the proposed lengthening, but most will need the frame for a number of months, but in some it in place on the limb for over a year. 
This process offers a controlled homogeneous environment to assess clinically the effect of LIPUS on bone healing. If bone healing was demonstrated to be accelerated by using LIPUS this would enable the (often cumbersome) frame to be removed at an earlier date, reducing the burden upon the patient, and it would also support the efficacy of LIPUS for accelerating bone healing in general.
In this multicentre double blind RCT we examined LIPUS compared with placebo for patients undergoing distraction osteogenesis. Our hypothesis was that patients using LIPUS would have a shortened maturation phase compared to placebo, which would allow the frame to be removed at an earlier time point.


Methods
Ethical approval was obtained from the Multi-Centre Research Ethics Committee for Scotland (MREC/02/10/5).
Study population
Patients were enrolled from four orthopaedic centres across the United Kingdom (xxxxxxxxxxx) during a four year period (2003 to 2006). The trial centres included were tertiary referral units that had a specialist interest in limb reconstruction using Ilizarov techniques.
Study participants were skeletally mature (physis closed) and required a tibial lengthening of at least 2.5cm and no more than 10cm. All males and non-pregnant females were included. The only other inclusion criterion was that the corticotomy had to be within the proximal metaphysis of the tibia and distal to the tibial tuberosity.
Patients were excluded if they: were unable to give informed consent or unable to comply with the study protocol, were pregnant, were enrolled in another trial, or if they had associated injuries that would inhibit adherence to study protocol. Chronic alcoholics, users of non-steroidal anti-inflammatory drugs (including Cox II inhibitors) and patients with pathological fractures or systemic diseases that affected bone healing were also excluded.
Outcome measures
Patient demographics, body mass index (BMI) and smoking status were recorded after the patient gave their consent to take part in the trial. As the healing at the docking site may decide the time of frame removal rather than the healing of the regenerate itself, the primary outcome measure was the time at which the principle investigator (blinded to the treatment group) determined the frame could be removed. The decision as to when the frame was to be removable was determined by anterio-posterior and lateral radiographs taken at 4 week intervals from time of surgery. The kV and tube to radiographic film were standardised throughout all four study centres. The regenerate was considered mature when there was bone continuity observed between proximal and distal bone ends with no fibrous interzone, which was homogenous and the width of the regenerate was equal to that of the adjacent bone on one view and at least 75% on the other orthogonal view.    
	The time at which the regenerate was considered mature was the time taken at which the new bone no longer needed external fixator support, i.e. the frame could be removed from the point of view of the regenerate. However, the time taken for removal of the frame was proportional to the amount of lengthening required, with a longer lengthening requiring a longer time in the frame. As previously reported ADDIN REFMGR.CITE 13-15, a regenerate maturation index (RMI) was calculated to normalise for the amount of distraction in each patient. The RMI was calculated by dividing the time to regenerate maturation by the achieved distraction length (days/cm).
Weight bearing through the affected limb was also measured as a clinical marker of maturation of the regenerate bone. Weight bearing was measured at each four week review using a standardize and calibrated scales across all study centres. Patients were asked to stand on a platform at the same level as the scale while weight bearing on the contralateral limb, they were then asked to place the affected limb on the scale and bear weight up to their tolerance limit. This was recorded as a direct measure of weight in kg and as a percentage of the patient’s body weight prior to frame application.  
Study treatments
All patients underwent a standardised division of the bone and Ilizarov frame application for limb lengthening. The bone was divided by one of two accepted methods (standardised per centre): multiple drill holes completed with an osteotome or by using a Gigli saw. All corticotomies were performed in the proximal tibial metaphysis and distal to the tibial tubercle. A standard Ilizarov frame was used at the lengthening site in the proximal tibia. 
After the frame had been applied and the bone divided a seven day latency period was observed (no lengthening) in keeping with standard practice for distraction osteogenesis. After this latency period the distraction phase was commenced at a rate of 0.75mm/day, (in three increments of 0.25mm). The duration of the lengthening phase was dictated by the required lengthening and ranged from 33 days to 133days for the minimum distraction of 2.5cm and maximum of 10cm, respectively. Following the distraction phase the treatment was continued throughout the maturation phase which lasted approximately four times as long as the distraction phase. During this phase the regenerate bone to matured, allowing the patient to be able to bear weight without the support of the frame. 
All patients commenced use of the assigned device (active or placebo) once a centimeter of distraction had been achieved, which was approximately twenty days from surgery. The investigator at each centre instructed the patient exactly when to commence treatment and the exact site the device was to be used, which was at the centre of the regenerate as indicated by the X-rays. The device used for all patients was the Exogen 2000+ (Smith & Nephew).
Randomisation
Patients were randomised to active or placebo (control) devices according to a computer generated randomisation scheme. Computer randomisation codes were generated for each centre in groups of four, which included two active and two placebo devices. Once a patient gave informed consent to participate in the trial the device was assigned from the randomisation code for that centre. Randomisation was on a 1:1 basis, stratified by centre, which ensured that any clustering effect on the study outcomes related to the centre itself was equally distributed in the trial arms. 
Blinding
The operating surgeon and the patient were blind to the treatment randomisation, as the active and placebo devices were identical and the signal in the active device provided no audible or physical sensation. In addition all staff involved in checking, entering, and analysing questionnaire responses were also blind to the treatment allocation.
Sample size and statistical analysis
The primary outcome measure was time of maturation of the regenerate bone standardized for distraction length. The study was powered to detect a difference of 6.2days/cm in lengthening between the two study groups; i.e. for a 5cm distraction it would be possible to remove the frame one month earlier. This was based on prior literature reporting a standard deviation of 8days/cm for RMI, and using a one-sided analysis with an alpha significance of 0.05 and a 90% power. Using these variables it was calculated that 30 patients would need to be recruited to both arms of the study. 
Differences between treatment groups were assessed as per protocol (PP) and an intention to treat (ITT) basis (Figure 1). The primary efficacy hypothesis was tested using a PP analysis (conditional) and ITT (unconditional). The study was powered to demonstrate a difference in the RMI (Regenerate Maturation Index) which was assessed between the groups (Wilcoxon rank sum). Secondary end points assessed between the two groups were return to weight bearing and compliance with device usage, and covariates affecting time until frame removal. Weight bearing was assessed as an absolute weight and as a percentage of the patients weight between the groups using mixed effects random slopes model. The device compliance was assessed as a percentage of compliance with daily use and a percentage of treatment time (of the prescribed 20 minute period).  Time of frame removal was assessed with a Kaplan-Meier plot and a Log-rank test to assess the difference according to group. Covariates affecting time until frame removal were assessed using proportional hazards regression (Cox).
The statistical analysis plan was agreed with the independent data management committee at the start of the study and sign off after data collection, but prior to breaking of the code. A Mann Whitney U test was used to assess linear variables and a chi square (or Fishers Exact test if less 10) was used to assess dichotomous variables between the groups. All statistical analysis was carried out with SPSS version 17. A p-value of <0.05 (5% significance level) was defined as statistically significant.



Results
Patients
There were 32 patients randomised to an active device and 30 were randomised to the placebo (control) device and were defined as the ITT cohort (Figure 2). There were two (6.3%) protocol violations in the 32 patients randomised to active treatment and five (16.7%) in the placebo group. The reasons for the violations were: second operation to divide the bone after 14 days (n=3), stimulating agent (BMP, bone morphogenetic protein) used at the regenerate site (n=1), incomplete pre-operative documentation (n=1), systemic disease that affects bone healing (Stills disease, n=1) and withdrew from study (n=1).  There was no significant difference in the number of protocol violations between the two groups (Fisher’s exact test p=0.249). Hence, there were 30 patients in the active device group and 25 patients the placebo device group managed PP. There were no differences in the age, BMI, race or smoking status between the two groups for those managed as ITT or PP, however a higher percentage of female patients in the placebo device group (Table I). 
Primary outcome
There was no statically significant difference in the distraction length or time to maturation of the regenerate (time from initiation of ultrasound treatment to frame removal) between the two groups for those managed as ITT and PP (Table II). The resultant Regenerate Maturation Index (RMI) was also not statically significant different, but there was a trend towards a significantly longer time until maturation for the active device group compared to the placebo group for patients managed by ITT (Table II).


Secondary outcomes
Analysis of weight bearing was performed in the ITT dataset. Three patients had less than two recorded weight bearing measures, all of which were in the active device group, and were excluded from analysis as the modelling approach used required a change in the weight bearing to be measured. The mean initial weight bearing was 29.1 (16.4 SD, range 0 to 75) kg and 32.2 (21.4 SD, range 0 to 82) kg for the 29 patients in the active device group and the 30 in the placebo group respectively, which was not statistically significant (Man Whitney U test, p=0.543).  Multiple linear regression analysis was performed to compare the slopes of the active versus the placebo group while controlling for distraction length, which failed to demonstrate a statistical difference between the groups (t=-1.31, df=54, p=0.545). 
Compliance with the prescribed use of the ultrasound device was assessed from two aspects, one being use on a daily basis and the other being the time applied when it was used for the ITT cohort. To achieve 100 percent compliance the device should have been used for 20 minutes every day. Patient compliance varied, but overall 75 percent of patients were more than 50 percent compliant with their prescribe treatment regime (Figures 3 and 4). The median daily compliance for the active group was 78.4 (inter quartile range (IQR) 43.5 to 93.7) percent and 81.8 (IQR 45.9 to 96.2) percent in the placebo group (Mann Whitney U Test, p=0.71).  The median compliance with time applied of the device for the active group was 91.0 (IQR 59.7 to 97.5) percent and 94.7 (IQR 77.2 to 97.9) percent for the placebo group (Mann Whitney U Test, p=0.80). Multiple linear regression analysis demonstrated no statically significant correlation between compliance of use (p=0.262) or time (p=0.664) of application of the ultrasound device with regenerate maturation, RMI (R2 0.07). 
Survival analysis of time to maturation was performed using Kaplan Meier survival curves. The overall time to regenerate maturation from initiation of treatment was not statistically different between active and placebo groups for the PP (Log rank, p=0.434) or ITT (Log rank, p=0.641) cohorts (Figures 5 and 6). Covariates assessed for their influence on time to maturation were specified in the analysis plan using Cox regression analysis. Two models were used: model A: treatment group, distraction length, and model B: treatment group, distraction length and covariate. No statistically significant difference was observed between active and placebo groups when controlling for distraction length (Model A) or distraction length and each covariate (Model B) for both PP and ITT cohorts (Table III). The only significant covariate identified was current smoking with a hazard ratio 0.47, which equates to an approximate reduction in bone healing of approximately 50 percent at any time point compared to those who did not smoke.


Discussion
This study has not demonstrated any association of accelerated bone healing with LIPUS. Although there is an increasing trend to use LIPUS for all fractures with an aim to shorten the patient’s period of rehabilitation and prevent delayed union we were not able to support the general use of this treatment for distraction osteogenesis. 
	The only significant factor affecting bone healing, after adjusting for distraction length, was the smoking status of the patient. Those who were current smokers had a significantly longer time to bone healing, being 50 percent longer than those who did not smoke. This is supported by a recent systematic review which found smoking negatively influences the healing of the tibia.16 However, we have quantified the effect in our study in a controlled homogenous environment, which is an original observation. The influence of LIPUS on bone healing remained non-significant after adjusting for smoking status between the groups. Hence, it would seem that more attention should be paid to the smoking status of the patient and whether interventions to help smoking cessation at the time of their injury result in earlier bone healing. We acknowledge the confidence interval for the effect of smoking from 0.22 to 0.97, however it does support the clinical data regarding the association of delayed and non-union of acute fractures with smoking. ADDIN REFMGR.CITE 17 
The level of compliance with the prescribed LIPUS treatment could have been higher, but 75 percent of patients complied with more than 50 percent of the regime. This rate is consistent with other studies using the LIPUS device ADDIN REFMGR.CITE 8;18;19 and represents what would happen in a real clinical setting should it be used on a routine basis. In addition we demonstrated no correlation between compliance with LIPUS treatment and bone healing, and does not support the argument that our negative results are due to failure of compliance. The second limitation was the number of protocol violations (n=7). However, analysis of the bone healing for both the ITT and PP groups demonstrated no difference between those patients who had LIPUS and those who did not. 
A major irregularity of the study by present day standards was that the study protocol and statistical analysis plan were not registered prior to commencing recruitment. The study was conceived in 2000 following which all lead investigators agreed to a defined protocol (appendix). Recruitment began in 2003. Thus there was an equivalent process of having an agreed written protocol and statistical analysis plan prior to recruitment, but at the time of the study these were not routinely registered. The delay in getting this study to publication was due to independent data analysis and a prolonged delay in obtaining the data from the company, which was confounded by the parent company selling on the technology to a subsidiary company. 
Defining maturation of the regenerate as the primary end point measure may be a limitation, rather than using the real time to frame removal. The time at which the frame was actually removed may vary because of healing at the docking site rather than because of healing of the regenerate. The primary outcome measure was chosen to be the assessment of maturation of the regenerate site (time at which it was considered that the frame could be removed) by a single blinded observer who was an experienced limb reconstruction surgeon (AHRWS). All of the radiographs were scored using standardised strict assessment criteria before the code was broken for the active/placebo devices. 
The major strength of this trial is the robust prospective design, being blind to both the patient and assessor. This is the first double blind randomised controlled assessing the effect of LIPUS on bone healing in distraction osteogenesis. This controlled technique offers a stable environment to assess bone healing and the factors that may influence it.  The bone is divided in a similar fashion in the same region of the tibia and stabilised using the same technique. This may explain why our results are in contrast to previous studies that have reported the results of LIPUS for acute fractures, which are heterogeneous in nature.  NICE having reviewed the available evidence, which is primarily from case cohorts, concluded that LIPUS was a beneficial treatment for delayed unions/non-unions.6 The lack of a clinical detectable effect in distraction osteogenesis could be for several reasons, such as there being different cells in this clinical scenario or that the system is already being driven at a maximal rate, whereas in delayed union and non-union there is the potential to accelerate the rate of healing.
The secondary analysis of covariates affecting bone healing is an interesting aspect of this study, finding that smoking significantly affected healing. Thus, if LIPUS has a beneficial effect it is likely to be smaller than the detrimental effect of smoking. Identification of smoking as an inhibitory factor of bone healing and quantifying the effect of this may influence clinic management of patients undergoing distraction osteogenesis and fracture healing. This is an area of future investigation that needs to be addressed, if smoking inhibits healing does stopping reverse this effect? In addition, smokers may be an at risk group who could benefit for LIPUS to aid their bone healing, returning it to that observed in non-smokers.
Conclusions
In conclusion, and in contrast to trend and previous studies we have not demonstrated any effect of LIPUS on bone healing during distraction osteogenesis. Smoking seems to inhibit bone repair and to lengthen the healing period by up to 50%. Suggesting that smoking cessation would reduce their period of bone healing and that all such patients should be offered help to quit prior to commencing distraction osteogenesis.
Conflict of Interest
The authors declare no conflicts of interest
Declarations
This study was supported by a research grant for Smith and Nephew.


 ADDIN REFMGR.REFLIST References

	(1) 	Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997; 103(2A):20S-25S.
	(2) 	Heckman JD, Sarasohn-Kahn J. The economics of treating tibia fractures. The cost of delayed unions. Bull Hosp Jt Dis 1997; 56(1):63-72.
	(3) 	Gaston MS, Simpson AH. Inhibition of fracture healing. J Bone Joint Surg Br 2007; 89(12):1553-1560.
	(4) 	Higgins A, Glover M, Yang Y, Bayliss S, Meads C, Lord J. EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing: a NICE medical technology guidance. Appl Health Econ Health Policy 2014; 12(5):477-484.
	(5) 	Padilla F, Puts R, Vico L, Raum K. Stimulation of bone repair with ultrasound: a review of the possible mechanic effects. Ultrasonics 2014; 54(5):1125-1145.
	(6) 	EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing. http://www.nice.org.uk/guidance/mtg12 (​http:​/​​/​www.nice.org.uk​/​guidance​/​mtg12​). National Institue for Health and Care Excellence 2013; MTG12.
	(7) 	Griffin XL, Parsons N, Costa ML, Metcalfe D. Ultrasound and shockwave therapy for acute fractures in adults. Cochrane Database Syst Rev 2014; 6:CD008579.
	(8) 	Heckman JD, Ryaby JP, McCabe J, Frey JJ, Kilcoyne RF. Acceleration of tibial fracture-healing by non-invasive, low-intensity pulsed ultrasound. J Bone Joint Surg Am 1994; 76(1):26-34.
	(9) 	Kristiansen TK, Ryaby JP, McCabe J, Frey JJ, Roe LR. Accelerated healing of distal radial fractures with the use of specific, low-intensity ultrasound. A multicenter, prospective, randomized, double-blind, placebo-controlled study. J Bone Joint Surg Am 1997; 79(7):961-973.
	(10) 	Lubbert PH, van der Rijt RH, Hoorntje LE, van der Werken C. Low-intensity pulsed ultrasound (LIPUS) in fresh clavicle fractures: a multi-centre double blind randomised controlled trial. Injury 2008; 39(12):1444-1452.
	(11) 	Handolin L, Kiljunen V, Arnala I, Pajarinen J, Partio EK, Rokkanen P. The effect of low intensity ultrasound and bioabsorbable self-reinforced poly-L-lactide screw fixation on bone in lateral malleolar fractures. Arch Orthop Trauma Surg 2005; 125(5):317-321.
	(12) 	Papakostidis C, Bhandari M, Giannoudis PV. Distraction osteogenesis in the treatment of long bone defects of the lower limbs: effectiveness, complications and clinical results; a systematic review and meta-analysis. Bone Joint J 2013; 95-B(12):1673-1680.
	(13) 	Gold SM, Wasserman R. Preliminary results of tibial bone transports with pulsed low intensity ultrasound (Exogen). J Orthop Trauma 2005; 19(1):10-16.
	(14) 	El-Mowafi H, Mohsen M. The effect of low-intensity pulsed ultrasound on callus maturation in tibial distraction osteogenesis. Int Orthop 2005; 29(2):121-124.
	(15) 	Dudda M, Hauser J, Muhr G, Esenwein SA. Low-intensity pulsed ultrasound as a useful adjuvant during distraction osteogenesis: a prospective, randomized controlled trial. J Trauma 2011; 71(5):1376-1380.
	(16) 	Patel RA, Wilson RF, Patel PA, Palmer RM. The effect of smoking on bone healing: A systematic review. Bone Joint Res 2013; 2(6):102-111.
	(17) 	Clement ND, Goudie EB, Brooksbank AJ, Chesser TJ, Robinson CM. Smoking status and the Disabilities of the Arm Shoulder and Hand score are early predictors of symptomatic nonunion of displaced midshaft fractures of the clavicle. Bone Joint J 2016; 98-B(1):125-130.
	(18) 	Schofer MD, Block JE, Aigner J, Schmelz A. Improved healing response in delayed unions of the tibia with low-intensity pulsed ultrasound: results of a randomized sham-controlled trial. BMC Musculoskelet Disord 2010; 11:229.
	(19) 	Roussignol X, Currey C, Duparc F, Dujardin F. Indications and results for the Exogen ultrasound system in the management of non-union: a 59-case pilot study. Orthop Traumatol Surg Res 2012; 98(2):206-213.



Tables
Table I. Pre-operative case-mix variables for study groups according to treatment as per protocol and intension to treat.
Case-mix variables	Per protocol	Intension to treat
	Active(n=30)	Placebo(n=25)	Active(n=32)	Placebo(n=30)
				
Age (years: mean, SD)	37.2 (12.9)	38.4 (12.0)	37.8 (12.9)	37.0 (12.1)
				
Gender  	Male	9 (30)	2 (8)	10 (31)	2 (7)
(n, %)	Female	21 (70)	23 (92)	22 (69)	28 (93)
				
BMI (mean, SD)	26.9 (4.5)	28.0 (5.7)	27.0 (4.7)	27.6 (5.5)
				
Race  	Caucasian	32 (100)	2 (92)	32 (100)	28 (93)
(n, %)	Non-Caucasian	0	23 (8)	0	2 (7)
				
Smoking 	Never	10 (33)	12 (48)	12 (38)	13(43)
(n, %)	Stopped	12 (40)	10 (40)	12 (38)	13 (43)
	Current	8 (27)	3 (12)	8 (25)	4 (13)
				


Table II. Achieved distraction length, time to regenerate maturation (frame removal) and RMI for the study groups according to treatment as per protocol and intension to treat.
Case-mix variables	Per protocol			Intension to treat		
	Active(n=30)	Placebo(n=25)	95% CI	p-value*	Active(n=32)	Placebo(n=30)	95% CI	p-value*
								
Distraction length (cm: mean, SD)	4.3 (2.4)	4.3 (1.8)	-1.2 to 1.1	0.515	4.4 (2.3)	4.3 (1.7)	-1.0 to 1.1	0.578*
								
Time to regenerate maturation** (days: mean, SD)	257.7 (101.9)	227 (102.7)	-24.4 to 86.6	0.211	256.6 (101.2)	233.8 (98.3)	-27.9 to 73.5	0.394
								
RMI**(days/cm: mean, SD)	66.9 (24.2)	56.8 (24.7)	-3.2 to 23.4	0.054	65.8 (24.7)	60.8 (27.3)	-8.2 to 18.2	0.226
*Wilcoxon rank sum
** Time from initiation of treatment with pulsed ultrasound



Table III. Covariate analysis (Cox regression analysis) for time to regenerate maturation from start of treatment for patients managed as per protocol and as intension to treat.
Covariates in model	Per protocol	Intension to treat
	Hazard ratio(95% CI)	p-value	Hazard ratio(95% CI)	p-value
Model A				
	Active device	0.78 (0.45 to 1.37)	0.389	0.89(0.53 to 1.49)	0.654
	Distraction length	0.76 (0.64 to 0.90)	0.002	0.76 (0.65 to 0.90)	0.001
				
Model B*				
	Age	0.98 (0.95 to 1.00)	0.068	0.99 (0.96 to 1.01)	0.208
	Height	0.98 (0.94 to 1.01)	0.205	0.99 (0.96 to 1.02)	0.451
	Weight	1.00 (0.99 to 1.02)	0.683	1.01 (0.99 to 1.03)	0.406
	BMI	1.04 (0.97 to 1.10)	0.272	1.05 (0.98 to 1.11)	0.149
	Female	1.02(0.47 to 2.16)	0.965	0.93 (0.45 to 1.93)	0.841
	Infection	1.63 (0.75 to 4.00)	0.252	1.54 (0.67 to 3.52)	0.309
	Race	0.48 (0.11 to 2.11)	0.332	0.39 (0.09 to 1.71)	0.214
	Comorbidity	0.98(0.41 to 2.33)	0.958	0.82(0.36 to 1.85)	0.628
	Smoke currently	0.47(0.22 to 0.97)	0.042	0.50 (0.25 to 1.00)	0.051
	Osteotomy technique	0.82 (0.27 to 2.49)	0.723	0.86 (0.32 to 2.32)	0.390
*All models include distraction length and the treatment group as covariates. No significant (p=0.654) difference was observed between the active and placebo groups when adjusting for the covariates in each model.  


Figures
Figure 1. Flow chart indicating patient assignment to analysis dataset according to treatment as per protocol (PP) and intension to treat (ITT).
Figure 2. CONSORT patient flow diagram. 
PP = per protocol ITT = intention to treat 
Figure 3. Percentage compliance with daily application of the ultrasound device according to randomisation group.
Figure 4. Percentage compliance with treatment time (20 minutes) of the ultrasound device on a daily basis according to randomisation group.

 Figure 5. Kaplan Meier curve for time to regenerate maturation from treatment initiation for patients managed as per protocol.
Figure 6. Kaplan Meier curve for time to regenerate maturation from treatment initiation for patients managed as intension to treat.


